|1.||Hayes, Robert A: 1 article (01/2004)|
|2.||Quinn, John P: 1 article (01/2004)|
|3.||Gunderson, Shana M: 1 article (01/2004)|
|4.||Danziger, Larry H: 1 article (01/2004)|
|5.||Waites, Ken B: 1 article (12/2003)|
|6.||Crabb, Donna M: 1 article (12/2003)|
|7.||Duffy, Lynn B: 1 article (12/2003)|
|8.||Nilius, Angela M: 1 article (10/2003)|
|9.||Hensey-Rudloff, Dena: 1 article (10/2003)|
|10.||Balli, Darlene J: 1 article (10/2003)|
12/01/2003 - "ABT-492 has potential for treatment of infections due to these microorganisms."
10/01/2003 - "The profile of ABT-492 suggested that it may be a useful agent for the treatment of community-acquired respiratory tract infections, as well as infections of the urinary tract, bloodstream, and skin and skin structure and nosocomial lung infections."
|3.||Respiratory Tract Infections (Respiratory Tract Infection)
01/01/2004 - "ABT-492 is a novel quinolone with potent activity against gram-positive, gram-negative, and atypical pathogens, making this compound an ideal candidate for the treatment of community-acquired pneumonia. "
01/01/2004 - "We therefore compared the in vitro pharmacodynamic activity of ABT-492 to that of levofloxacin, an antibiotic commonly used for the treatment of pneumonia, through MIC determination and time-kill kinetic analysis. "
|5.||Plague (Bubonic Plague)